Marina Biotech has recently acquired the Smarticles intellectual property portfolio of Novosom, further expanding its RNA delivery platform intellectual property estate.

Marina Biotech said that the new patent issuance provides protection to processes by which amphoteric liposomes are prepared.

Marina Biotech president and CEO Michael French said they are pleased that their recent acquisitions are already generating value for us on the intellectual property front.

“This patent, covering amphoteric liposomal delivery, is a significant addition to our existing RNA delivery intellectual property estate that also includes the DiLA2 delivery platform, the tkRNAi platform (bacterial delivery platform) and our peptide nanoparticle delivery platform,” French said.

“We will continue to expand our IP position by aggressively seeking issued claims and developing additional novel formulations for safe and effective systemic and local delivery of RNA-based therapeutics.”